This inventor holds 60 USPTO granted patents and 4 published patent applications, plus 1 CIPO patent and 7 EPO patents, primarily in Glucokinase Activators (CPC class C07D). Top assignees: Novo Nordisk A/s, Transtech Pharma, Inc., Eli Lilly and Company. Active years: 1992-2015.
Inventors with similar research interests:
Company Filing History:
44 out of 1,801 
3 out of 49 
2 out of 4,508 
Years Active: 1992-2015
Areas of Expertise:
Title: Lone Jeppesen - Pioneering Innovations in Therapeutic Agents
Introduction:
Lone Jeppesen, a visionary inventor hailing from Virum, Denmark, has established himself as a trailblazer in the field of pharmaceutical inventions. With an impressive portfolio of 60 patents to his name, Jeppesen's contributions have significantly impacted the healthcare industry.
Latest Patents:
Jeppesen's recent patents showcase his dedication to developing cutting-edge therapeutic agents. The inventions "Aryl Carbonyl Derivatives as Therapeutic Agents" and "Heteroaryl-Ureas and Their Use as Glucokinase Activators" highlight his expertise in enhancing glucokinase activity for the treatment and management of various diseases.
Career Highlights:
Jeppesen's professional journey includes esteemed tenures at renowned companies such as Novo Nordisk A/S, where he honed his skills and expertise in pharmaceutical research and development. His innovative approach and passion for creating impactful solutions have cemented his reputation as a leader in the field.
Collaborations:
Throughout his career, Jeppesen has collaborated with talented individuals in the industry, such as Per Sauerberg and Paul Stanley Bury. These partnerships have been instrumental in bringing his groundbreaking inventions to fruition and advancing the field of pharmaceuticals.
Conclusion:
In conclusion, Lone Jeppesen's relentless pursuit of innovation and his groundbreaking inventions have positioned him as a driving force in the development of therapeutic agents. His valuable contributions to the healthcare sector continue to inspire and pave the way for future advancements in the field.